{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:31:29Z","timestamp":1787016689981,"version":"build-2736575974"},"reference-count":54,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>\n                    Fluoroquinolones remain some of the more commonly prescribed antimicrobial agents in the United States, despite the wide array of reported side effects that are associated with their use. In 2019, the Clinical and Laboratory Standards Institute revised the fluoroquinolone antimicrobial susceptibility testing breakpoints for both\n                    <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n                    and\n                    <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n                    .\n                  <\/jats:p>","DOI":"10.1128\/jcm.02072-18","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T08:53:42Z","timestamp":1556614422000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa"],"prefix":"10.1128","volume":"57","author":[{"given":"Tam T.","family":"Van","sequence":"first","affiliation":[{"name":"Department of Pathology, Harbor-UCLA Medical Center, Los Angeles, California, USA"},{"name":"Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Minejima","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao An","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, USC School of Pharmacy, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Butler-Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Keck School of Medicine of USC, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing. M100. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.04.006"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-009-7108-9"},{"key":"e_1_3_1_5_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 29th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing; 29th informational supplement. M100-S29. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_1_6_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters version 9.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140030-00003"},{"key":"e_1_3_1_8_2","volume-title":"Outpatient antibiotic prescriptions\u2014United States, 2015","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. 2015. Outpatient antibiotic prescriptions\u2014United States, 2015. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/antibiotic-use\/community\/pdfs\/Annual-Report-2015.pdf."},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-016-0007-y"},{"key":"e_1_3_1_10_2","volume-title":"Cipro (ciprofloxacin HCl) tablet, for oral use, and Cipro (ciprofloxacin hydrochloride), for oral suspension, package insert","author":"Bayer HealthCare Pharmaceuticals","year":"2016","unstructured":"Bayer HealthCare Pharmaceuticals. 2016. Cipro (ciprofloxacin HCl) tablet, for oral use, and Cipro (ciprofloxacin hydrochloride), for oral suspension, package insert. Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019537s086lbl.pdf."},{"key":"e_1_3_1_11_2","volume-title":"Levaquin (levofloxacin) tablets, Levaquin (levofloxacin) oral solution, Levaquin (levofloxacin) injection, for intravenous use, and Levaquin (levofloxacin in 5% dextrose) injection, for intravenous use, package insert","author":"Janssen Pharmaceuticals","year":"2008","unstructured":"Janssen Pharmaceuticals. 2008. Levaquin (levofloxacin) tablets, Levaquin (levofloxacin) oral solution, Levaquin (levofloxacin) injection, for intravenous use, and Levaquin (levofloxacin in 5% dextrose) injection, for intravenous use, package insert. Janssen Pharmaceuticals, Inc., Raritan, NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021721s020_020635s57_020634s52_lbl.pdf."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.7.885"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.08.020"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aambs.2014.09.002"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/664763"},{"key":"e_1_3_1_17_2","volume-title":"Antibiotic resistance threats in the United States, 2013","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf."},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2847-x"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000475"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00101-11"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/653931"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1054\/drup.2001.0196"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1525-1527.2006"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1609"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv228"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr220"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/383320"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2749-2755.2003"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1665-1670.2002"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4009-4014.2005"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq211"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm536"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki079"},{"key":"e_1_3_1_35_2","unstructured":"USCAST. 2018. Breakpoint tables for interpretation of MICs and zone diameters version 4.0. https:\/\/app.box.com\/s\/h3kiuhnullzacgv1quvz5sax03no3loh."},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.03.016"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C419"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.2.125"},{"key":"e_1_3_1_39_2","unstructured":"USCAST. 2018. Quinolone in vitro susceptibility test interpretative criteria evaluations version 1.3. https:\/\/app.box.com\/s\/1e014sx90frwv4oml52erzcp2rw3wa9s."},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00580-08"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-017-0202-4"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.827-829.2003"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis600"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2008.03.004"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00294-07"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy432"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix942"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00635-16"},{"key":"e_1_3_1_49_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 28th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement. M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_1_50_2","volume-title":"Development of in vitro susceptibility testing criteria and quality control parameters","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Development of in vitro susceptibility testing criteria and quality control parameters, 5th ed. M23. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"5"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.04.025"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.07.026"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.02.004"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2057-2"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01797-18"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02072-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02072-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T05:26:32Z","timestamp":1646457992000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.02072-18"}},"subtitle":[],"editor":[{"given":"Colleen Suzanne","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1128\/JCM.02072-18"],"URL":"https:\/\/doi.org\/10.1128\/jcm.02072-18","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"2019-06-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02072-18"}}